Stockscreener 앱 받기
38.56
5.44%
-2.22
시간 외 거래:
38.68
0.12
+0.31%
전일 마감가:
$40.78
열려 있는:
$38.625
하루 거래량:
9.33M
Relative Volume:
2.30
시가총액:
$16.67B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
16.79
EPS:
2.297
순현금흐름:
$827.02M
1주 성능:
+2.72%
1개월 성능:
+6.81%
6개월 성능:
+17.74%
1년 성능:
+45.40%
1일 변동 폭
$38.39
$40.10
1주일 범위
$36.03
$41.24
52주 변동 폭
$24.05
$41.24
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.56 | 17.42B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Will Royalty Pharma plc (RPD) stock maintain strong growthQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next yearVolume Spike & Real-Time Price Movement Reports - newser.com
Using Python tools to backtest Royalty Pharma plc strategies2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Applying chart zones and confluence areas to Royalty Pharma plc2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveJuly 2025 Pullbacks & Stock Timing and Entry Methods - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedJuly 2025 Intraday Action & Low Drawdown Investment Strategies - newser.com
Is Royalty Pharma plc (RPD) stock attractive post correctionChart Signals & Daily Momentum Trading Reports - newser.com
Can Royalty Pharma plc stock rebound after recent weaknessAnalyst Downgrade & Weekly Top Gainers Alerts - newser.com
Analyzing net buyer seller activity in Royalty Pharma plcTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Why retail investors pile into Royalty Pharma plc stock2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
(RPRX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsQuarterly Trade Review & Growth Focused Entry Reports - newser.com
Achmea Investment Management B.V. Invests $1.23 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Published on: 2025-11-07 09:50:08 - newser.com
Royalty Pharma Plc Hits New 52-Week High of $38.09 - Markets Mojo
C WorldWide Group Holding A S Has $22.60 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Position Increased by Bryn Mawr Trust Advisors LLC - MarketBeat
Royalty Pharma raises 2025 top line guidance to $3.2B–$3.25B amid strong portfolio expansion - MSN
Is Royalty Pharma plc stock a safe investment in uncertain marketsWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
Why analysts remain bullish on Royalty Pharma plc stockQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Is Royalty Pharma plc reversing from oversold territoryPortfolio Performance Summary & Consistent Growth Equity Picks - newser.com
Goldman Sachs raises Royalty Pharma stock price target to $45 on strong results By Investing.com - Investing.com South Africa
Goldman Sachs raises Royalty Pharma stock price target to $45 on strong results - Investing.com Australia
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
What’s the recovery path for long term holders of Royalty Pharma plc2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-11-06 05:49:05 - newser.com
Royalty Pharma (RPRX) PT Raised to $45 at Goldman Sachs - StreetInsider
How Royalty Pharma plc (RPD) stock performs in easing cyclesPortfolio Return Summary & Safe Entry Momentum Tips - newser.com
Royalty Pharma Reports Strong Q3 2025 Results - TipRanks
Royalty Pharma Q3 2025 slides: Portfolio receipts up 11%, guidance raised - Investing.com Nigeria
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates - sharewise.com
Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
Royalty Pharma’s Q3 2025 Earnings Call Highlights - TipRanks
Royalty Pharma (RPRX) Earnings Soar 52% as Margin Surge Challenges Bearish Narratives - Yahoo Finance
Does Royalty Pharma plc qualify in momentum factor screeningMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
Is Royalty Pharma plc stock supported by strong fundamentalsJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - fcp.pa.gov.br
Can Royalty Pharma plc stock beat analyst upgradesGlobal Markets & Long-Term Safe Investment Plans - newser.com
Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar
Is Royalty Pharma plc (RPD) stock undervalued historicallyJuly 2025 Opening Moves & Target Return Focused Stock Picks - Fundação Cultural do Pará
Royalty Pharma stock hits 52-week high at 38.01 USD By Investing.com - Investing.com Australia
Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025 - MarketScreener
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Royalty Pharma Raises Earnings Outlook After Beating Estimates - Finimize
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... By GuruFocus - Investing.com Canada
Earnings call transcript: Royalty Pharma Q3 2025 reports robust growth By Investing.com - Investing.com Australia
Royalty Pharma Q3 2025 Earnings Call Transcript - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
0.70%
자본화:
|
볼륨(24시간):